Amneal Pharmaceuticals stock gained 1.15 percent on October 2

Published on 10/05/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amneal Pharmaceuticals stock carries a USD 21.00 average target from 10 brokers after Q2 adjusted EPS of USD 0.30 beat USD 0.24 estimates. Revenue reached USD 796.2 million.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals stock (ISIN US03168L1052) was last at USD 20.30 on NASDAQ on October 2, 2026, at 4:00 p.m. ET, up 1.15 percent from the prior close. The company had just added an FDA-approved specialty injectable to its portfolio, giving the market a concrete product catalyst.

Lanreotide adds a specialty product

According to Amneal Pharmaceuticals on September 18, 2026, the FDA approved the company's lanreotide injection in a 120 mg/0.5 mL prefilled syringe. Amneal said the product would launch immediately and had received Competitive Generic Therapy designation.

The commercial opportunity is measurable: U.S. annual sales for the reference product Somatuline Depot reached USD 983 million for the 12 months ended July 2026, according to the company release. Amneal also said it would use dedicated in-house manufacturing capacity, linking the approval to production rather than a licensing-only arrangement.

Q2 revenue reached USD 796.2 million

Amneal reported second-quarter 2026 revenue of USD 796.2 million and adjusted EPS of USD 0.30, compared with the USD 0.24 consensus estimate, MarketBeat reported. The USD 0.06 adjusted EPS difference gives the quarterly result a clearer benchmark than revenue alone.

The company's fiscal 2026 adjusted EPS guidance stands at USD 0.96-1.06, while the analyst estimate cited by MarketBeat is USD 0.94. That gap places the midpoint of management's range above the cited consensus, although the range itself shows the company's expected earnings span.

Analysts see limited target upside

MarketBeat reported on September 26, 2026, that 10 brokers carried a Moderate Buy consensus, with nine Buy ratings and one Hold rating. Their average 12-month price target was USD 21.00, which lies 3.4 percent above the USD 20.30 reference price.

The individual recommendations show a wide but still constructive range of views: Barclays raised its target from USD 16.00 to USD 20.00 on September 17, 2026, while Leerink Partners initiated coverage at Outperform with a USD 23.00 target on September 9, 2026, according to MarketBeat. The contrast matters because the average target is only modestly above the latest quoted price.

Stock stays below its yearly high

AMRX traded between USD 20.00 and USD 20.54 on October 2, 2026, with volume of 2,815,676 shares. Its 52-week range was USD 9.56 to USD 21.18, leaving the latest price 4.2 percent below the high and 112.3 percent above the low.

Amneal Pharmaceuticals stock therefore combines a fresh specialty-drug launch with a second-quarter adjusted EPS beat and a valuation reference near the top of its yearly range. The next market test is whether lanreotide contributes to the company's specialty and complex-generic growth beyond the USD 796.2 million quarterly revenue base.